A Study of Rofecoxib Versus Naproxen in the Treatment of Chinese Patient With Rheumatoid Arthritis
Information source: Merck
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Rheumatoid Arthritis
Intervention: MK0966; rofecoxib (Drug); Comparator: naproxen tablet 500 mg (Drug)
Phase: Phase 4
Status: Terminated
Sponsored by: Merck Official(s) and/or principal investigator(s):
Medical Monitor, Study Director, Affiliation: Merck
Summary
A study to compare rofecoxib versus naproxen in the treatment of Chinese patients with
rheumatoid arthritis.
Clinical Details
Official title: A Multicenter, Randomized, Parallel-Group, 8-Week, Double-Blind, and Active Comparator-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Rofecoxib Tablet 25 mg Once Daily Versus Naproxen Table 500 mg Twice Daily in the Treatment of Chinese Patient With Rheumatoid Arthritis
Study design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Primary outcome: Tender joint countswollen joint count patient's global assessment of disease activity investigator's global assessment of disease activity
Secondary outcome: Patient pain asessmentpatient's global assessment of response to therapy investigator's global assessment of response to therapy
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Chinese males or females at least 18 years of age with rheumatoid arthritis
Locations and Contacts
Merck Sharp & Dohme (China) Ltd., Beijing 100738, China
Additional Information
Starting date: February 2004
Last updated: November 30, 2006
|
